PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
1.42%
Revenue growth below 50% of CRWV's 23.55%. Michael Burry would check for competitive disadvantage risks.
No Data
No Data available this quarter, please select a different quarter.
1.42%
Gross profit growth below 50% of CRWV's 25.15%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-221.14%
EBITDA decline while CRWV shows 33.05% growth. Joel Greenblatt would examine position.
-219.44%
EBITDA margin decline while CRWV shows 7.69% growth. Joel Greenblatt would examine position.
-221.14%
Operating income decline while CRWV shows 169.93% growth. Joel Greenblatt would examine position.
-219.44%
Operating margin decline while CRWV shows 156.60% growth. Joel Greenblatt would examine position.
221.14%
Other expenses growth while CRWV reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
EPS decline while CRWV shows 23.08% growth. Joel Greenblatt would examine position.
-100.00%
Diluted EPS decline while CRWV shows 23.08% growth. Joel Greenblatt would examine position.
3.28%
Share count reduction exceeding 1.5x CRWV's 20.32%. David Dodd would verify capital allocation.
3.28%
Diluted share reduction exceeding 1.5x CRWV's 20.32%. David Dodd would verify capital allocation.